Question 64

Therapeutic duplication would be a concern for a patient prescribed both Eliquis and rivaroxaban.

Therapeutic duplication occurs when a patient is prescribed two medications that serve the same therapeutic purpose, which can lead to increased risk of adverse effects. In this case, both Eliquis and rivaroxaban are anticoagulants, making their concurrent use particularly concerning.

A) rivaroxaban

Rivaroxaban is an anticoagulant, similar to Eliquis, as both medications are used to prevent and treat blood clots. Prescribing both simultaneously increases the risk of bleeding complications due to overlapping mechanisms of action, thereby constituting therapeutic duplication.

B) eletriptan

Eletriptan is a medication used to treat migraines and does not share a therapeutic class with Eliquis. Therefore, there is no therapeutic duplication concern with this combination, as they serve different medical purposes.

C) eltrombopag

Eltrombopag is a thrombopoietin receptor agonist used to treat certain blood disorders by increasing platelet counts. It does not function as an anticoagulant like Eliquis, so there is no risk of therapeutic duplication in this scenario.

D) risperidone

Risperidone is an antipsychotic medication used to treat mental health disorders and does not have any anticoagulant properties. As a result, there is no concern for therapeutic duplication when prescribed alongside Eliquis.

Conclusion

Rivaroxaban is the only option that poses a risk of therapeutic duplication when prescribed with Eliquis, as both medications are anticoagulants that could lead to increased bleeding risks. The remaining options—eletriptan, eltrombopag, and risperidone—do not overlap in therapeutic class with Eliquis, thus eliminating any concern for therapeutic duplication.